

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:
022406Orig1s000

OFFICE DIRECTOR MEMO

Office Director Decisional Memo

Date	(electronic stamp)
From	Richard Pazdur, MD
Subject	Office Director Decisional Memo
NDA/BLA #	22406/S000
Applicant Name	Janssen Pharmaceuticals, Inc.
Date of Submission	1/04/11
PDUFA Goal Date	7/03/11
Proprietary Name /Established (USAN) Name	Xarelto/rivaroxaban
Dosage Forms / Strength	Oral Tablets/10 mg film-coated
Proposed Indication(s)	For the prophylaxis of deep vein thrombosis and pulmonary embolism in patients undergoing hip replacement surgery or knee replacement surgery
Action/Recommended Action for NME:	Approval

Material Reviewed/Consulted OND Action Package, including:	
Division Director	Ann T. Farrell, MD, Acting Division Director
Medical Officer Review	Min Lu, M.D./Kathy Robie-Suh, M.D./Ph.D.
Statistical Review	Qing Xu, Ph.D./Mark Rothmann, Ph.D.
Pharmacology Toxicology Review	Yash Chopra, PhD./Adebayo Lanionu, Ph.D. and Patricia Harlow, PhD./ Thomas Papoian, Ph.D.
CMC Review/OBP Review	Joyce Crich, Ph.D./Janice Brown, Ph.D. and Tapash Ghosh, Ph.D./Patrick Marroum, Ph.D.
Microbiology Review	N/A
Clinical Pharmacology Review	Joseph Grillo, Ph.D./Julie Bullock, Ph.D.
DDMAC	James Dvorsky
DSI	Susan Thompson, M.D./Tejashari Purohit Sheth, M.D./Leslie Ball, M.D.
CDTL Reviews	Kathy Robie-Suh, M.D., Ph.D.
OSE/DMEPA	Denise V. Baugh, PharmD, BCPS/Carol Holquist, RPh
OSE/Epidemiology	Kate Gelperin, M.D./John Senior, M.D.
Other - statistical safety	John Yap, Ph.D./ LaRee Tracy, Ph.D./Aloka Chakravarty, Ph.D.
Other – Pediatrics Maternal Health Team	Elizabeth L. Durmowicz, M.D./Hari C. Sachs, M.D./Lisa Mathis, M.D. Dr. Upasana Bhatnagar, MD/ Karen Feibus, M.D./ Lisa Mathis, M.D.
Other- Pharmacometrics	Nitin Mehrotra, Ph.D./Christine Garnett, Ph.D.

OND=Office of New Drugs

DDMAC=Division of Drug Marketing, Advertising and Communication

OSE= Office of Surveillance and Epidemiology

1. Introduction

Xarelto is an oral Factor Xa inhibitor initially submitted on July 22, 2008 for the prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing hip replacement surgery or knee replacement surgery. On May 27, 2009, a complete response letter was issued in the first cycle due to the need to clarify chemistry, manufacturing and control (CMC) issues; need for additional understanding of potential safety issues; and need for additional clarification of data integrity issues. The applicant responded to the complete response letter on January 4, 2011.

Xarelto has been approved by the European Medicines Agency since May 6, 2009.

2. Background

Four drugs are approved in the prevention of venous thromboembolism (VTE) in the setting of hip and/or knee replacement surgery. All these drugs are administered parenterally (enoxaparin, fondaparinux, dalteparin and unfractionated heparin). Warfarin is the only oral anticoagulant approved for the prophylaxis of venous thrombosis and PE in general. However, warfarin is not specifically indicated for the prevention of VTE in the perioperative period but is widely used.

Unlike warfarin, rivaroxaban does not require anticoagulation parameter monitoring of the prothrombin time (PT). However, rivaroxaban does prolong the partial thromboplastin time (PT) and partial thromboplastin time (PTT).

The original submission had four major trials submitted (RECORD 1, 2, 3, and 4) in support of the application. The first-cycle review team determined the trials supported an efficacy determination; however, a number of deficiencies were identified in the areas of CMC, clinical safety and data integrity. Therefore, a complete response letter was issued.

3. CMC/Device

The CMC reviewers recommend approval of this NDA and state:

"From a Chemistry, Manufacturing and Controls standpoint, this NDA is recommended for approval a 30 month shelf life for the drug product in HDPE bottles and a 18 month shelf life for the drug product in blisters, when stored at 20°-25°C (68°F - 77°F) or room temperature; excursions permitted to 15°C - 30°C (59°F - 86°F) [see USP Controlled Room Temperature]."

4. Nonclinical Pharmacology/Toxicology

The first cycle review did not identify any issues that would preclude approval from a nonclinical standpoint. In the 2-year carcinogenicity studies in CD-1 Mice and Wistar rats, a slight increase in tumors was noted in the Wistar rats study; however, this increase was not statistically significant. The observed increase does not affect the approvability of this NDA which is for short-term use.

5. Clinical Pharmacology/Biopharmaceutics

The recommended dose is 10 mg per day with or without food. Dose modification is suggested if used with a strong P-gp and CYP3A4 inducer.

There are no issues which would preclude approval of rivaroxaban based on the clinical pharmacology reviews. However, the clinical pharmacology review team is recommending additional post-marketing commitment (PMC) and requirements (PMR) to develop a lower dose of rivaroxaban and to evaluate the effect of renal impairment with the concurrent use of P-gp and moderate inhibitors of CYP3A4 on the PK, PD and safety of rivaroxaban (please refer to the action letter for these PMCs/PMRs).

6. Clinical Microbiology

Not applicable

7. Clinical/Statistical-Efficacy

During the first cycle review, the primary concerns regarding this application were safety (not efficacy) with a specific concern that there was insufficient safety information on hepatotoxicity to assess the full-risk benefit profile.

From Dr. Lu's first cycle review, "Four multi-center, randomized controlled trials (RECORD 1-4) were conducted... RECORD 1 and 2 studies were conducted in patients undergoing hip replacement surgery (THR) and RECORD 3 and 4 studies were in patients undergoing knee replacement surgery (TKR).

In all 4 RECORD trials, rivaroxaban 10 mg once daily administered orally at least 6 to 8 hours after surgery was compared with enoxaparin administered subcutaneously. The enoxaparin dosing regimen was 40mg once daily starting 12 hours preoperatively in RECORD 1-3 studies and was 30 mg twice daily starting 12 to 24 hours postoperatively in RECORD 4 study. The durations of active treatment for rivaroxaban and enoxaparin were similar in the RECORD studies with the exception of RECORD 2, in which treatment duration of Rivaroxaban was much longer than enoxaparin control (rivaroxaban 35 days versus enoxaparin 13 days). The dose regimen of enoxaparin (40 mg once daily) control in RECORD 3 study is not a recommended dose regimen of enoxaparin for the prophylaxis of DVT in patients undergoing TKR in the United States.

Altogether a total of 12,729 patients (6356 in the rivaroxaban group and 6373 in the enoxaparin group were randomized in 4 RECORD studies and 8,512 (67%) (4248 in the rivaroxaban group and 4264 in the enoxaparin group) were included in the Modified Intent to Treat (MITT) population for the primary efficacy analysis. About 30-39% of randomized patients in RECORD studies were excluded from MITT population mainly due to no adequate assessment of DVT.

The primary efficacy endpoint was a composite endpoint of total VTE consisting of any DVT (proximal and/or distal), non-fatal PE, or death from all causes at the end of treatment in all 4 RECORD studies.

The statistical analyses supporting approval from the statistical team's review are in the table below.

Table 1. Summary of Primary Efficacy Endpoint Analysis Results (Total VTE)

Study	Rivaroxaban % (n/N)	Enoxaparin % (n/N)	Absolute Risk Reduction	p-value
RECORD 1	1.1% (18/1595)	3.7% (58/1558)	2.6%	p<0.0001
RECORD 2	2.0% (17/864)	9.3% (81/869)	7.3%	p<0.0001
RECORD 3	9.6% (79/824)	18.9% (166/878)	9.3%	p<0.0001
RECORD 4	6.9% (67/965)	10.1% (97/959)	3.2%	p=0.012

The Division of Scientific Investigations (DSI) identified some problematic sites and investigators during inspection and assessment. Thus, the statistical review team also performed sensitivity analyses excluding the known unreliable sites. The statistical review team reanalyzed the data removing these sites where there were drug accountability and other issues. For each RECORD trial, the sensitivity analysis using the modified ITT population demonstrates a statistically significant difference in favor of rivaroxaban for the primary endpoint. The results are provided in table 2 below.

Table 2. Summary of Primary Efficacy Endpoint Analysis Results (Total VTE) Excluding Unreliable Sites

Study	Rivaroxaban % (n/N)	Enoxaparin % (n/N)	Absolute Risk Reduction	p-value
RECORD 1	1.1% (17/1513)	3.9% (57/1473)	2.8%	p<0.0001
RECORD 2	2.1% (17/828)	8.4% (70/830)	6.3%	p<0.0001
RECORD 3	9.7% (79/813)	18.8% (164/871)	9.1%	p<0.0001
RECORD 4	7.1% (53/742)	10.8% (79/731)	3.7%	p=0.0174

Removing the problematic investigators/sites suggested that the results are still supportive of efficacy claims. However, the Agency has additional concerns regarding the study conduct and data collected in RECORD 4 which are discussed later.

8. Safety

During the first review cycle, the review team identified areas for rigorous safety review: bleeding events, cardiovascular events, hepatotoxicity, and renal toxicity.

Bleeding Events:

Review of the bleeding events revealed an increase in major bleeding events for the rivaroxaban treated patients; however, the difference was not statistically significant.

Cardiovascular Events:

No statistically significant differences were noted between treatment groups during treatment. However, a slightly higher incidence of ischemic stroke was noted after subjects stopped rivaroxaban treatment. The significance of this increase is unclear.

Hepatotoxicity:

The greatest concern during the first cycle review was for hepatotoxicity. The review team requested additional long term follow-up data from the ROCKET studies where rivaroxaban was used for stroke prophylaxis in patients with atrial fibrillation. The longer term data did not reveal a significantly different liver toxicity profile compared with warfarin and enoxaparin.

Renal toxicity:

There were slightly higher incidences of creatinine and urea elevations in the rivaroxaban-treated subjects compared with the active control subjects.

In the second cycle, Dr. Lu concluded:

"The other adverse events reported more frequently with rivaroxaban as compared to the control were pruritus, wound healing complications, pain in extremity, increased muscle tone and cramping, wound secretion, blister, syncope, and dysuria in clinical trials. Other significant adverse events reported associated with rivaroxaban treatment in post-marketing spontaneous reports were cerebral hemorrhage, epidural hematoma, hypersensitivity reactions including anaphylactic shock, agranulocytosis, and Steven-Johnson syndrome".

There is a lack of knowledge about a method to reverse anticoagulation (including excessive anticoagulation). The division will request from the sponsor a method to amass cases of major bleeding seen post-approval, collect information on rivaroxaban dosing, outcome of major bleeding, and any treatment for the major bleeding.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.